---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Definition and etiology"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Definition and etiology. Topics: Definition: upper airway collapse during sleep with apneas and hypopneas, Definition: narrowing of the upper airway that impairs ventilation during sleep, Diagnostic criteria: ICSD-3-TR criteria reproduced in the VA/DoD guideline, Diagnostic criteria: ICSD-3 definition and variability in the hypopnea definition, and 5 further topics. 9 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Definition: upper airway collapse during sleep with apneas and hypopneas

> “Obstructive sleep apnea (OSA) is the most common type of sleep disordered breathing (SDB).”
> “OSA is characterized by upper airway collapse during sleep resulting in partial or complete interruption of airflow (i.e., respiratory events including apneas and/or hypopneas that may be associated with oxygen desaturation, hypercapnia, and/or arousals and sleep fragmentation).”
> “Hypopnea is a 30% or greater decrease in airflow that is at least 10 seconds in duration and is associated with either a ≥3% oxygen desaturation or arousal.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.1-2"></a>

### Definition: narrowing of the upper airway that impairs ventilation during sleep

> “This paper focuses on diagnostic issues related to the diagnosis of OSA, a breathing disorder characterized by narrowing of the upper airway that impairs normal ventilation during sleep.”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.1-3"></a>

### Diagnostic criteria: ICSD-3-TR criteria reproduced in the VA/DoD guideline

> “((A and B) or C) + D must be met”
> “The patient complains of sleepiness, fatigue, insomnia, or other symptoms leading to impaired sleep-related quality of life.”
> “The patient wakes with breath holding, gasping, or choking”
> “Five or more predominantly obstructive respiratory events (obstructive and mixed apneas, hypopneas, or respiratory effort related arousals [RERAs]) per hour of sleep during a PSG or per hour of monitoring (HSAT)”
> “Fifteen or more predominantly obstructive respiratory events (obstructive and mixed apneas, hypopneas, or respiratory effort related arousals [RERAs]) per hour of sleep during a PSG or per hour of monitoring (HSAT)”
> “The symptoms are not better explained by another current sleep disorder, medical disorder, medication or substance use.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.1-4"></a>

### Diagnostic criteria: ICSD-3 definition and variability in the hypopnea definition

> “The third edition of the International Classification of Sleep Disorders (ICSD-3) defines OSA as a PSG-determined obstructive respiratory disturbance index (RDI) ≥ 5 events/h associated with the typical symptoms of OSA (e.g., unrefreshing sleep, daytime sleepiness, fatigue or insomnia, awakening with a gasping or choking sensation, loud snoring, or witnessed apneas), or an obstructive RDI ≥ 15 events/h (even in the absence of symptoms).”
> “However, it should be noted that there is variability in the definition of a hypopnea event.”
> “Depending on which definition is used, the AHI may be considerably different in a given individual.”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.1-5"></a>

### Severity categories by respiratory event index

> “Mild OSA is defined as ≥5 to <15 events per hour with the presence of symptoms; moderate OSA is defined as ≥15 to <30 events per hour; and severe OSA is defined as ≥30 events per hour.”
> “However, the apnea-hypopnea index (AHI) or respiratory event index (REI) are not the sole indicators of OSA severity in a given patient, as this parameter does not account for oxygen desaturation frequency or oxygen saturation nadir, the duration of the respiratory event, sleep fragmentation, or comorbid illnesses.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.1-6"></a>

### Risk factors: age, sex, body mass index, and menopause

> “The prevalence of OSA increases with age, body mass index (BMI), and males (2:1), but after menopause the risk in women increases.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.1-7"></a>

### Risk factors: demographic, anatomical, and behavioral factors

> “OSA incidence and prevalence is expected to rise with obesity rates; however, it is not solely related to obesity.”
> “Obstructive sleep apnea is more prevalent in individuals with factors that include being older, male, a minority race, have a high body mass index, large neck circumference, craniofacial abnormalities, are menopausal, and those with health behaviors such as smoking and alcohol use.”

Source: [Frost & Sullivan (2016)](https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf)

<a id="topic-2.2.1.1-8"></a>

### Risk factors: high-risk clinical populations

> “High-risk patients include those who are obese, those with congestive heart failure, atrial fibrillation, treatment refractory hypertension, type 2 diabetes, stroke, nocturnal dysrhythmias, pulmonary hypertension, high-risk driving populations (such as commercial truck drivers), and those being evaluated for bariatric surgery (Consensus).”

Source: [Epstein et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2699173/)

<a id="topic-2.2.1.1-9"></a>

### Obesity as a risk factor: share of adults with OSA who have obesity, AHI of 5 or more with 4% desaturation hypopnea rule (individual participant data meta-analysis with Apnimed authors)

> “Obesity is a well-established risk factor for obstructive sleep apnea (OSA).”
> “OSA severity was quantified using the apnea-hypopnea index (AHI, all apneas plus hypopneas with ≥4% oxygen desaturation/hour).”
> “Among 12,860 adults (mean ± SD age: 66.6 ± 7.3 years), 7222 (56.2%) had OSA (AHI ≥5 events/h) and 3309 (25.7%) had obesity (BMI ≥30 kg/m2).”
> “IPD meta-analysis showed 31.5% [95% CI: 16.8–48.5] of individuals with OSA had obesity and 44.4% [36.5–52.5] had overweight status (25 ≤ BMI < 30).”
> “Odds ratios for OSA in subgroups of individuals with overweight and obesity compared to BMI <25 kg/m2 were 2.18 [1.73–2.76] and 4.84 [3.09–6.00], respectively.”
> “LG, L T-M, JY, JC work for Apnimed.”

Source: [Esmaeili et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12051718/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
